27 Apr

SCOTUS setback won’t end FTC’s focus on pharma patent strategies

The Supreme Court has dealt a blow to the Federal Trade Commission’s ability to police anti-competitive behaviour, but pharma companies can expect scrutiny of reverse-payments and sham patent litigation to increase

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth